Hemodialysis clearance of encainide and metabolites.
The disposition of encainide and metabolites O-desmethylencainide (ODE) and 3-methyl-ODE (MODE) was evaluated in a 31-year-old hemodialysis patient following a 25 mg oral dose during an interdialytic period and a second 25 mg oral dose 48 h later, 2 h before a hemodialysis procedure. The inter- and intradialytic elimination half-lives were not different for encainide and its metabolites ODE and MODE. The hemodialysis clearance of encainide, MODE, and ODE are all less than 10% of the creatinine clearance of the dialyzer. Thus, hemodialysis does not result in clinically significant removal of encainide or its metabolites.
Halvorsen
M B
MB
College of Pharmacy, University of Minnesota, Minneapolis.
Whitmer
J T
JT
Halstenson
C E
CE
D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000378:metabolism*; D016700:Encainide / Q000031:analogs & derivatives* / Q000378:metabolism*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy; D008297:Male; D006435:Renal Dialysis
C072660:3-methyl-O-desmethylencainide; D000889:Anti-Arrhythmia Agents; C033635:O-demethylencainide; D016700:Encainide